Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Filters

2021 - 20242

Settings

Author: search.filters.author.Malhan, SimtenSubject: search.filters.subject.Direct costs

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Economic Burden Of Short-Acting Beta-2 Agonist (Saba) Overuse Among Asthma Patients In Türkiye: A Cost Analysis With Respect To The Updated Gina Treatment Recommendations
    (BMC PULMONARY MEDICINE, 2024-10-21) Yorgancioglu, Arzu; Aksu, Kurtulus; Cura, Ceyhun; Yaman, Yigit; Dinc, Melda; Malhan, Simten
    BackgroundThis cost of illness study aimed to determine economic burden of short-acting beta 2-agonist (SABA) overuse in T & uuml;rkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations.MethodsA total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the T & uuml;rkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (>= 0 canisters/year) vs. GINA-recommended (0-2 canisters/year, hypothetical population) SABA use and in subgroups of appropriate use (0-2 canisters/year, real population) vs. overuse (>= 3 canisters/year) of SABA with extrapolation of SABINA T & uuml;rkiye data to the T & uuml;rkiye asthma population.ResultsRecommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [>= 0 canisters/year] vs. GINA-recommended [0-2 canisters/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be 20.43 million and 427.65 million in terms of severe exacerbations, and to be 829,352 and 7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be 456.11 million. Appropriate use (0-2 canisters/year) vs. overuse (>= 3 canisters/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of 16.38 million and 385.59 million, respectively in terms of severe exacerbations, and a total 11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be 413.27 million.ConclusionsThe estimated annual total economic burden arising from not applying recommended SABA use (456.11 million) and SABA overuse (413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country.
  • No Thumbnail Available
    Item
    Economic Burden Of Lung Cancer In Turkey: A Cost Of Illness Study From Payer Perspective
    (2021) Cicin, Irfan; Oksuz, Ergun; Karadurmus, Nuri Nuri; Malhan, Simten; Gumus, Mahmut; Yilmaz, Ulku; Cansever, Levent; Cinarka, Halit; Cetinkaya, Erdogan; Kiyik, Murat; Ozet, Ahmet; 0000-0002-5723-5965; 34173876; K-8238-2012
    Background This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be euro8772), for non-small-cell lung cancer to be euro10,167. Total annual direct medical cost was euro497.9 million, total annual indirect medical cost was euro1.1 billion and total economic burden of lung cancer was euro1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.